Clinical Trial Update: Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients [Phase 3]

View source ↗

Summary

Open-label extension of pegunigalsidase alfa (PRX-102) at 2 mg/kg every 4 weeks in adults with Fabry disease; this Phase 3 study is currently ACTIVE_NOT_RECRUIT…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Pegunigalsidase alfa (pegunigalsidase alfa)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Fabry Disease | Phase 3 | Status: ACTIVE_NOT_RECRUITING